Page last updated: 2024-10-24

P-TEFb complex binding

Definition

Target type: molecularfunction

Binding to a P-TEFb complex. [GOC:pga, PMID:18391197]

P-TEFb, a critical regulator of transcription elongation, exerts its influence by binding to and phosphorylating the C-terminal domain (CTD) of RNA polymerase II (RNAPII). This interaction is crucial for facilitating the transition from transcription initiation to elongation. The P-TEFb complex comprises two subunits: cyclin-dependent kinase 9 (CDK9) and cyclin T1 or cyclin T2. CDK9, a serine/threonine kinase, possesses the catalytic activity responsible for phosphorylating the CTD. The CTD of RNAPII is a highly conserved, repetitive sequence consisting of heptapeptide repeats with the consensus sequence YSPTSPS. P-TEFb specifically targets Serine 2 (Ser2) within these repeats, leading to its phosphorylation. Phosphorylation of Ser2 on the CTD serves as a molecular switch, triggering a cascade of events that promote elongation. Notably, the recruitment of P-TEFb to the transcription machinery is tightly regulated. It is believed that P-TEFb exists in an inactive state within the cell, bound to the 7SK snRNP complex. Upon receiving signals, such as the presence of paused RNAPII or the activation of signaling pathways, P-TEFb is released from the 7SK snRNP complex and becomes available for recruitment to the transcription site. The precise mechanism of P-TEFb recruitment varies depending on the specific gene and regulatory context. Once recruited to the transcription site, P-TEFb phosphorylates Ser2 on the CTD of RNAPII, facilitating the transition from initiation to elongation. This phosphorylation event triggers several downstream effects, including: (1) recruitment of elongation factors, such as SII and TFIIS, which enhance the processivity of RNAPII; (2) dissociation of negative elongation factors (NELFs), which hinder elongation; (3) recruitment of splicing factors, facilitating the removal of introns from the nascent RNA transcript; (4) recruitment of polyadenylation factors, initiating the process of mRNA 3'-end processing. In summary, P-TEFb binding and its associated Ser2 phosphorylation of the CTD play a pivotal role in regulating transcription elongation, ensuring efficient and accurate production of mRNA molecules.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Bromodomain-containing protein 4A bromodomain-containing protein 4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60885]Homo sapiens (human)

Compounds (45)

CompoundDefinitionClassesRoles
alprazolamalprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.

Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
organochlorine compound;
triazolobenzodiazepine
anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
ly 303511LY 303511: inhibitor of phosphatidylinositol 3-kinaseN-arylpiperazine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first sourcechromones;
morpholines;
organochlorine compound
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
entinostatbenzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
sb 2021904-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinaseimidazoles;
organofluorine compound;
phenols;
pyridines
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
vorinostatvorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
dicarboxylic acid diamide;
hydroxamic acid
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
ferrocin cN-methyl-2-quinolone: structure in first source
n-methylpyrrolidone1-methylpyrrolidin-2-one: structure in first source

N-methylpyrrolidin-2-one : A member of the class of pyrrolidine-2-ones that is pyrrolidin-2-one in which the hydrogen attached to the nitrogen is replaced by a methyl group.
lactam;
N-alkylpyrrolidine;
pyrrolidin-2-ones
polar aprotic solvent
4-Methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-onebenzodiazepine
nitroxolinenitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.

nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd
C-nitro compound;
monohydroxyquinoline
antifungal agent;
antiinfective agent;
antimicrobial agent;
renal agent
n-hydroxysuccinimideN-hydroxysuccinimide: structure
lenalidomidearomatic amine;
dicarboximide;
isoindoles;
piperidones
angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
2-methyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-4-oneorganonitrogen heterocyclic compound;
oxacycle
methyl indole-3-carboxylatemethyl indole-3-carboxylate : The methyl ester of indole-3-carboxylic acid.indoles;
methyl ester
metabolite
2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-1-benzopyran-4-oneflavones
romidepsindepsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.cyclodepsipeptide;
heterocyclic antibiotic;
organic disulfide
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
belinostathydroxamic acid;
olefinic compound;
sulfonamide
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
panobinostatpanobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.

Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.
cinnamamides;
hydroxamic acid;
methylindole;
secondary amino compound
angiogenesis modulating agent;
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
volasertibBI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source
nu 74418-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first sourcedibenzothiophenes
bi 2536
N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamidesulfonamide
tg101209N-alkylpiperazine;
N-arylpiperazine;
pyrimidines;
secondary amino compound;
sulfonamide
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
fedratinibfedratinib: a selective small-molecule inhibitor of JAK2sulfonamide
ro3280RO3280: inhibits polo-like kinase 1; structure in first source
bi d1870
xmd 8-92XMD8-92 : A dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a [2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino substituent. It is an inhibitor of the BMK1 kinase pathway.pyrimidobenzodiazepineprotein kinase inhibitor
lrrk2-in1LRRK2-IN1: inhibits leucine-rich repeat kinase 2; structure in first sourcearomatic amine;
aromatic ether;
N-acylpiperidine;
N-alkylpiperazine;
pyrimidobenzodiazepine;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
jq1 compoundcarboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
dinaciclibpyrazolopyrimidine
gsk525762amolibresib: mimicks acetylated histones; structure in first sourcebenzodiazepine
LSM-6732organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
tert-butyl ester
gsk1210151aGSK1210151A: inhibitor of the BET family of proteins; structure in first sourceimidazoquinoline
i-bet726
pelabresibCPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first sourcemonochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide
antineoplastic agent;
bromodomain-containing protein 4 inhibitor
MS-417MS-417 : A member of the class of thienotriazolodiazepines that is the methyl ester of [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetic acid. A bromodomain and extra-terminal domain (BET)-specific inhibitor that belongs to a group of thienodiazepine-based compoundsmethyl ester;
monochlorobenzenes;
thienotriazolodiazepine
sf 1126SF 1126: an LY294002 prodrug and pan PI3K inhibitor; structure in first source
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide2-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide: a probe for bromo and extra C-terminal domain proteins; structure in first sourcequinazolines
cpi203CPI203: a BET protein bromodomain inhibitor
pf-06687252PF-06687252: a SMARCA2/4 bromodomain inhibitor; structure in first source

PFI-3 : An azabicycloalkane that is (1R,4R)-2,5-diazabicyclo[2.2.1]heptane which is substituted at position 2 by a 3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl group and at position 5 by a pyridin-2-yl group. It is a potent and selective inhibitor of polybromo 1 (Kd = 48 nM), SMARCA2 and SMARCA4 (Kd = 89 nM) bromodomains.
azabicycloalkane;
enone;
phenols;
pyridines
dBET6organic molecular entity
MZ1organic molecular entity
rvx 208apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation
pp242torkinib : A member of the class of pyrazolopyrimidines that is 1H-pyrazolo[3,4-d]pyrimidine substituted by isopropyl, 5-hydroxyindol-2-yl and amino groups at positions 1, 3 and 4 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.aromatic amine;
biaryl;
hydroxyindoles;
phenols;
primary amino compound;
pyrazolopyrimidine
antineoplastic agent;
mTOR inhibitor